SPRY Stock Analysis: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$7.20
-0.22 (-3.03%)
▼
5d:
-16.28%
30d:
-11.98%
90d:
-23.24%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 19, 2026
TODAY
Smart Money Accumulation
SPRY is down 15.0% this week, but smart money is accumulating calls. Top strike: $7.5 2026-06-18 with 1,661 OI. Call ratio: 89% View Scanner →
Strength: 10.0/10
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called SPRY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SPRY is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SPRY is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $7.20, which is considered oversold relative to its 30-day fair value range of $7.81 to $8.71.
Technical Outlook: Technically, SPRY is in a strong downtrend. The price is currently testing key support at $7.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.20 (+252.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRY is in a strong downtrend. The price is currently testing key support at $7.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.20 (+252.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.81 -
$8.71
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 252.9% below Wall St target ($26.20)
- WARNING: Recommendation downgraded due to -16.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.81 -
$8.71
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.03
Resistance Level
$9.57
Current Trend
Strong Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.80
Wall Street Target
$26.20
(+252.9%)
Revenue Growth (YoY)
-67.6%
Profit Margin
-203.3%
Share & Embed Analysis
Last updated: May 18, 2026 1:50 PM ET
Data refreshes hourly during market hours. Next update: 2:50 PM
Data refreshes hourly during market hours. Next update: 2:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 56 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
